These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16930864)

  • 1. Health related quality of life among both current and former injection drug users who are HIV-infected.
    Préau M; Protopopescu C; Spire B; Sobel A; Dellamonica P; Moatti JP; Carrieri MP;
    Drug Alcohol Depend; 2007 Jan; 86(2-3):175-82. PubMed ID: 16930864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.
    Bouhnik AD; Préau M; Vincent E; Carrieri MP; Gallais H; Lepeu G; Gastaut JA; Moatti JP; Spire B;
    Antivir Ther; 2005; 10(1):53-61. PubMed ID: 15751763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).
    Carrieri MP; Villes V; Raffi F; Protopopescu C; Preau M; Salmon D; Taieb A; Lang JM; Verdon R; Chene G; Spire B;
    Int J Drug Policy; 2007 Aug; 18(4):288-95. PubMed ID: 17689377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Psychosocial determinants of adherence to highly active antiretroviral therapy among injection drug users in Vancouver.
    Kerr T; Palepu A; Barness G; Walsh J; Hogg R; Montaner J; Tyndall M; Wood E
    Antivir Ther; 2004 Jun; 9(3):407-14. PubMed ID: 15259903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study.
    Roux P; Carrieri MP; Villes V; Dellamonica P; Poizot-Martin I; Ravaux I; Spire B;
    Addiction; 2008 Nov; 103(11):1828-36. PubMed ID: 18778390
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health-related quality of life and survival among HIV-infected patients receiving highly active antiretroviral therapy: a study of patients in the AIDS Therapy Evaluation in the Netherlands (ATHENA) Cohort.
    de Boer-van der Kolk IM; Sprangers MA; Prins JM; Smit C; de Wolf F; Nieuwkerk PT
    Clin Infect Dis; 2010 Jan; 50(2):255-63. PubMed ID: 20014949
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life in French people living with HIV in 2003: results from the national ANRS-EN12-VESPA Study.
    Préau M; Marcellin F; Carrieri MP; Lert F; Obadia Y; Spire B;
    AIDS; 2007 Jan; 21 Suppl 1():S19-27. PubMed ID: 17159583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment.
    Roux P; Carrieri MP; Cohen J; Ravaux I; Poizot-Martin I; Dellamonica P; Spire B
    Clin Infect Dis; 2009 Nov; 49(9):1433-40. PubMed ID: 19807275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Health-related quality of life and health locus of control beliefs among HIV-infected treated patients.
    Préau M; Vincent E; Spire B; Reliquet V; Fournier I; Michelet C; Leport C; Morin M;
    J Psychosom Res; 2005 Dec; 59(6):407-13. PubMed ID: 16310023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality of life, depression and fatigue among persons co-infected with HIV and hepatitis C: outcomes from a population-based cohort.
    Braitstein P; Montessori V; Chan K; Montaner JS; Schechter MT; O'Shaughnessy MV; Hogg RS
    AIDS Care; 2005 May; 17(4):505-15. PubMed ID: 16036236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.
    Muga R; Langohr K; Tor J; Sanvisens A; Serra I; Rey-Joly C; Muñoz A
    Clin Infect Dis; 2007 Aug; 45(3):370-6. PubMed ID: 17599317
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictors and consequences of negative physician attitudes toward HIV-infected injection drug users.
    Ding L; Landon BE; Wilson IB; Wong MD; Shapiro MF; Cleary PD
    Arch Intern Med; 2005 Mar; 165(6):618-23. PubMed ID: 15795336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug injection cessation among HIV-infected injecting drug users.
    Bouhnik AD; Carrieri MP; Rey D; Spire B; Gastaut JA; Gallais H; Obadia Y;
    Addict Behav; 2004 Aug; 29(6):1189-97. PubMed ID: 15236822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and impact of diarrhea on health-related quality of life in HIV-infected patients in the era of highly active antiretroviral therapy.
    Siddiqui U; Bini EJ; Chandarana K; Leong J; Ramsetty S; Schiliro D; Poles M
    J Clin Gastroenterol; 2007; 41(5):484-90. PubMed ID: 17450031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of long-cycle structured intermittent versus continuous HAART on quality of life in patients with chronic HIV infection.
    Powers AE; Marden SF; McConnell R; Leidy NK; Campbell CM; Soeken KL; Barker C; Davey RT; Dybul MR
    AIDS; 2006 Apr; 20(6):837-45. PubMed ID: 16549967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Withdrawal symptoms as a predictor of mortality in patients HIV-infected through drug use and receiving highly active antiretroviral therapy (HAART).
    Michel L; Giorgi R; Villes V; Poizot-Martin I; Dellamonica P; Spire B; Protopopescu C; Carrieri MP
    Drug Alcohol Depend; 2009 Jan; 99(1-3):96-104. PubMed ID: 18774237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related quality of life and patient-provider relationships in HIV-infected patients during the first three years after starting PI-containing antiretroviral treatment.
    Préau M; Leport C; Salmon-Ceron D; Carrieri P; Portier H; Chene G; Spire B; Choutet P; Raffi F; Morin M
    AIDS Care; 2004 Jul; 16(5):649-61. PubMed ID: 15223534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Health related quality of life among HIV-HCV co-infected patients].
    Préau M; Protopopescu C; Spire B; Dellamonica P; Poizot-Martin I; Villes V; Carrieri MP;
    Rev Epidemiol Sante Publique; 2006 Jul; 54 Spec No 1():1S33-1S43. PubMed ID: 17073128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative therapy use in HIV-infected patients receiving highly active antiretroviral therapy.
    Risa KJ; Nepon L; Justis JC; Panwalker A; Berman SM; Cinti S; Wagener MM; Singh N
    Int J STD AIDS; 2002 Oct; 13(10):706-13. PubMed ID: 12396542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of HAART and injection drug use on life expectancy of two HIV-positive cohorts in British Columbia.
    Lloyd-Smith E; Brodkin E; Wood E; Kerr T; Tyndall MW; Montaner JS; Hogg RS
    AIDS; 2006 Feb; 20(3):445-50. PubMed ID: 16439879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.